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Background: [11C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile ([11C]DASB) is currently the
mostly used radiotracer for positron emission tomography (PET) quantitative studies of the serotonin transporter
(SERT) in the human brain but has never been validated in dogs. The first objective was therefore to evaluate
normal [11C]DASB distribution in different brain regions of healthy dogs using PET. The second objective was to
provide less invasive and more convenient alternative methods to the arterial sampling-based kinetic analysis.
Results: A dynamic acquisition of the brain was performed during 90 min. The PET images were coregistered with
the magnetic resonance images taken prior to the study in order to manually drawn 20 regions of interest (ROIs).
The highest radioactivity concentration of [11C]DASB was observed in the hypothalamus, raphe nuclei and thalamus
and lowest levels in the parietal cortex, occipital cortex and cerebellum.
The regional radioactivity in those 20 ROIs was quantified using the multilinear reference tissue model 2 (MRTM2)
and a semi-quantitative method. The values showed least variability between 40 and 60 min and this time interval
was set as the optimal time interval for [11C]DASB quantification in the canine brain. The correlation (R2) between
the MRTM2 and the semi-quantitative method using the data between 40 and 60 min was 99.3 % (two-tailed
p-value < 0.01).
Conclusions: The reference tissue models and semi-quantitative method provide a more convenient alternative to
invasive arterial sampling models in the evaluation of the SERT of the normal canine brain. The optimal time
interval for static scanning is set at 40 to 60 min after tracer injection.
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In vivo imaging of the living brain can be performed
with positron emission tomography (PET), based on the
detection of two opposite 511 keV gamma-rays that re-
sult from the annihilation of a positron and a negatron.
The serotonergic system is one of the major neuro-
transmitter systems in the brain and is involved in a
variety of neuropsychiatric disorders including anxiety
disorders, schizophrenia, drug abuse, depression [1]* Correspondence: olivia.taylor@ugent.be
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dog, involvement of the serotonergic system in impul-
sive aggression, anxiety and compulsive disorders was
demonstrated with single photon emission computed
tomography [4–6]. Moreover, the serotonin enhancing
drugs used to treat human disorders are used in ca-
nine behavior medicine [7–9].
As the primary molecular target of the selective
serotonin reuptake inhibitors (SSRIs), the most com-
mon antidepressant drugs used in human medicine,
the serotonin transporter (SERT) has been the focus
of many studies in the past years. It is located on the
presynaptic nerve endings of serotonergic neurons. It
terminates neurotransmission by removing serotoninis distributed under the terms of the Creative Commons Attribution 4.0
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neuron) and modulates thus the extracellular sero-
tonin concentration [10].
Intensive research into development of suitable radio-
tracers to visualize and quantify this transporter with
functional imaging modalities occurred in the past years
in human (for review, [11]), but also in animal studies
[12–15]. The [11C]-3-amino-4-(2-dimethylaminomethyl-
phenylsulfanyl)-benzonitrile ([11C]DASB) is a recently
developed highly selective radiotracer with a nanomolar
affinity for the SERT for PET imaging [16]. Several stud-
ies in humans [17–21] showed that the regional distribu-
tion of the [11C]DASB was concordant with the known
densities of SERT in the brain [22]. It is currently the
most widely used radiotracer for PET quantitative stud-
ies of the SERT in human brain [2]. Up to now,
[11C]DASB has been investigated in rodents [23], pigs
[24], cats [12] and nonhuman primates [14], but never
in dogs. As canine behavioral and human neuropsychi-
atric disorders, such as anxiety, aggressive and compul-
sive disorders, share many similarities [25], the dog
represents a very interesting animal model for the inves-
tigation of human neuropsychiatric disorders. Further-
more, dogs represent a more practical and available
alternative to other laboratory animals such as rodents
or nonhuman primates. We already demonstrated in
past studies that the investigation of the canine brain
using radionuclides in general is feasible and that the re-
sults showed many similarities with human imaging
studies [4–6, 15, 26–30].
The two parameters usually used to evaluate the
[11C]DASB regional distribution are the total distribu-
tion volume (VT), representing the volume of tissue in
which the radioligand would have to distribute to reach
a concentration equal to that in the plasma [18], and the
binding potential of the nondisplaceable compartment
(BPND), referring to the ratio at equilibrium of the spe-
cifically bound radioligand to that of the nondisplaceable
radioligand in tissue [31]. The VT values can be esti-
mated using invasive kinetic methods, such as one-tissue
compartment (1TC), two-tissue compartment (2TC)
[32] and the linear graphical approach of Logan [33], re-
quiring the placement of an arterial catheter. The VT
values can then be used to calculate indirectly binding
potential values of the nondisplaceable compartment
(BPND) with the following equation [31]:
BPND ¼ VT−VNDVND ¼
VT
VND
−1
where BPND = ratio at equilibrium of specifically bound
(to receptor) radioligand to that of the nondisplaceable
(free and non-specifically bound) radioligand in tissue;
VT = distribution volume of distribution of the totalradioligand uptake in tissue in relation to total plasma
concentration; VND = volume of distribution of the non-
displaceable radioligand concentration in relation to
total plasma concentration [31]. Those BPND values can
also be estimated by reference tissue methods, eliminat-
ing the need of arterial samples [19, 34, 35].
To the authors’ knowledge, this is the first study using
PET imaging to evaluate SERT in the canine brain. The
first objective was to evaluate regional distribution of the
SERT in the normal canine brain with the tracer
[11C]DASB. The second objective was to determine the
equilibrium period (time interval during which regional
tracer distribution is stable) in an attempt to use a semi-
quantitative method to simplify the determination of the
regional radiotracer uptake by using data from a static
scan performed in that time interval. Furthermore, to
correlate the regional tracer distribution values obtained
with this semi-quantitative method with the data deter-
mined using a reference tissue method obtained from a
dynamic scan.Methods
Animals
Three healthy laboratory beagles and two purpose-bred
laboratory dogs (four males and one female, 4 to 8 years
old, weighting 11–32 kg) from the veterinary faculty of
Ghent were enrolled. This prospective study was ap-
proved and conducted in accordance with the guidelines
of the Ethical Committee of Ghent University (EC ap-
proval 2013/133).
The dogs were fasted for at least twelve hours before
the scan. A 22G venous catheter was placed in one of
the cephalic veins. The anesthetic protocol was similar
for both the magnetic resonance imaging (MRI) and
positron emission tomography/computed tomography
(PET/CT) scan. They were premedicated with dexme-
detomidin (Dexdomitor® 375 μg/m2 body surface area,
IM). Anesthesia was induced with propofol (Propovet®
2-3 mg/kg depending on effect, IV) and, after endo-
tracheal intubation, maintained with isoflurane (Isoflo®
1,2-1,4 % given to effect, administrated in 100 % oxy-
gen via a circle system). A 22G arterial catheter was
placed in one of the dorsal pedal arteries for the ar-
terial sampling. Two anesthesiologists performed
monitoring during and after anesthesia until the ani-
mals were fully awake.Imaging protocol
All five dogs underwent a MRI prior to the PET examin-
ation. Images were collected on a Siemens 3 T Magne-
tom Trio Tim system (Siemens Medical Systems,
Erlangen, Germany) using a phased-array spine coil and a
phased-array body matrix coil. Animals were anesthetized
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bore, with the front limbs extended caudally.
A structural scan was acquired using a T1-weighted
3D MPRAGE sequence with 176 sagittal slices. Fol-
lowing sequence parameters were used: TR = 2250 ms,
TE = 4.18 ms, TI = 900 ms, parallel acquisition
method = GRAPPA with acceleration factor = 2, matrix
size = 256 × 256, sagittal, FOV = 220 mm, flip angle =
8°, voxel size = 0.9 × 0.86 × 0.86 mm3.
The [11C]DASB was synthetized by N-methylation of
the precursor N-desmethyl-DASB with [11C]methyltri-
flate as previously described [36]. High chemical purities
(>99 %) were obtained. The specific activity at the time
of radiotracer injection was 43 ± 34 GBq/μmol.
Dogs were placed on the PET camera (Gemini PET/
CT, Philips, Eindhoven, The Nederlands) in sternal re-
cumbency with the front limbs extended caudally. A CT
scan was performed for attenuation correction. The
[11C]DASB was injected intravenously (mean activity ±
SD: 7,8 ± 1,6 mCi or 289 ± 60 MBq) after and before a
NaCl 0,9 % bolus. Data were acquired in list mode dur-
ing a 90 min dynamic acquisition of the brain. The ac-
quisition was started simultaneously to the injection of
the radiotracer. The list mode data were reconstructed
in 90 1-min frames for display purposes and determin-
ation of optimal scan time.Image analysis
A PET summation image of all frames and dynamic im-
ages were manually coregistered to each individual MR
images using PMOD software (PMOD Technologies,
Zurich, Switzerland).Fig. 1 Regions of interest representative of the [11C]DASB distribution in th
images fused with the corresponding MRI images. The following regions a
(OC), cerebellum (Cer), basal ganglia (BG), thalamus (Th), anterior cingulate
where the raphe nuclei are located (RN)Regions of interest (ROIs) were selected based on the
known distribution of the SERT and drawn based on an
anatomical atlas [37]. Twenty ROIs were manually delin-
eated in the raphe nuclei, hypothalamus, thalamus (left
and right), hippocampus (left and right), cerebellum (left
and right), frontal cortex (left and right), parietal cortex
(left and right), temporal cortex (left and right), occipital
cortex (left and right), basal ganglia (left and right), an-
terior cingulate gyrus and posterior cingulate gyrus
(Fig. 1). Within the cerebral cortex, only gray matter was
included into the ROIs to measure the PET activity dis-
tribution. The ROIs were delineated on the dorsal plane
T1-weighted images and extended to the co-registered
PET images. Regional radioactivity was determined for
each frame, corrected for decay and plotted versus time.
The effect of the scanning time on parameter’s stability
was evaluated using the ratio analysis [18]. The ratios of
five ROIs (raphe nuclei, thalamus, basal ganglia, frontal
cortex and occipital cortex) over the cerebellum were
determined for 20 min-scans starting every 10 min from
0 up to 70 min from the dynamic acquisition. The stand-
ard error of the ratio for each time interval was calcu-
lated to evaluate the stability of the parameters and
therefore the optimal scanning time.
Several methods have been described for the quantifi-
cation of [11C]DASB regional activity [18, 20, 32, 38]. In
this article, we measured the BPND values using the mul-
tilinear reference tissue model 2 (MRTM2) and the cere-
bellum was chosen as the reference region, assuming the
absence of SERT sites within this region [34]. As recom-
mended by Meyer in his review paper [3], we selected
the cerebellar cortex, excluding the vermis and keeping
distance from white matter and venous sinuses. Thee brain. Dorsal (left) and sagittal (right) sections of [11C]DASB PET
re displayed: frontal cortex (FC), temporal cortex (TC), occipital cortex
cortex (ACG), posterior cingulate cortex (PCG) and the brainstem area
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Technologies, Zurich, Switzerland). The nomenclature
used in this article is the consensus recommended by
Innis and coworkers [31].
In addition to the aforementioned quantitative com-
partmental analysis (MRTM2), a semi-quantitative
method was also evaluated using the ratio of the concen-
tration of radioactivity within the ROIs at the optimal
scanning time (determined based on the standard error
values), over the concentration of radioactivity within
the reference region (cerebellum). This simple quantifi-
cation method is preferred in clinical surroundings as
scan duration is considerably reduced and, similar to the
reference tissue models, does not require arterial sam-
pling. These values were then compared with those from
the MRTM2.Statistical analysis
To evaluate the usefulness of the semi-quantitative
method, the coefficient of determination (R2) between
[11C]DASB binding potential values in 5 different re-
gions (raphe nuclei, thalamus, basal ganglia, frontal cor-
tex and occipital cortex) obtained from the MRTM2 and
the values obtained from the semi-quantitative ratio ana-
lysis was calculated to estimate the correlation between
those two methods. Statistical analysis was performed
using SPSS software (version 18.0; SPSS, Chicago, IL).Fig. 2 Time-activity curves for regional brain radioactivity following intrave
regions of interest are displayed and represent the mean values of the five
regions with high (raphe nuclei and thalamus), intermediate (basal ganglia an
concentration. Except for the raphe nuclei (in the sagittal plane), the mean vaResults
Regional time-activity curves
Regional time-activity curves (TACs) were obtained for
each dog and each ROI. The highest radioactivity con-
centration of [11C]DASB was observed in the hypothal-
amus, raphe nuclei and thalamus, intermediate levels
were observed in the basal ganglia, hippocampus and
frontal cortex, modest levels in the anterior and poster-
ior cingulate gyri and temporal cortex, and low levels in
the parietal cortex, occipital cortex and cerebellum. The
TACs of six representative regions of different radio-
activity levels, high (raphe nuclei and thalamus), inter-
mediate (basal ganglia and frontal cortex) and low
(occipital cortex and cerebellum), are displayed in Fig. 2.
Optimal static scanning time
Time curves of the ratios of radioactivity of five ROIs
(raphe nuclei, thalamus, basal ganglia, frontal cortex and
occipital cortex) over the cerebellum are displayed in
Fig. 3. These curves demonstrate that the values reach a
plateau after approximately 40 min and become more
variable after approximately 60 min of scanning due to
the decay of 11C.
The ratios of the same five ROIs representing regions
of high (raphe nuclei and thalamus), moderate (basal
ganglia and frontal cortex) and low (occipital cortex)
SERT densities over the cerebellum were calculated for
20 min-scans starting every 10 min from the dynamicnous injection of [11C]DASB. Time-activity curves of six of the twenty
experiments. These six regions were chosen because they represent
d frontal cortex) and low (occipital cortex and cerebellum) radioactivity
lues of the right and left sides were taken for the five other regions
Fig. 3 Time curves of the ratio of five representative ROIs over the cerebellum. These curves demonstrate that the values reach a plateau after
approximately 40 min and become more variable after approximately 70 min of scanning. The optimal scanning time was determined from 40 to
60 min. The values correspond to the mean of the five experiments for five representative ROIs (raphe nuclei, thalamus, basal ganglia, frontal
cortex and occipital cortex). Except for the raphe nuclei (in the sagittal plane), the mean values of the right and left sides were taken for the four
other regions
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sess the stability of the parameters and the optimal scan-
ning time (Table 1). The values were demonstrated to be
less variable from 30 to 70 min, the standard error
values being 2.6 % when scanning from 30 to 50 min,
2.5 % from 40 to 60 min and 2.9 % from 50 to 70 min.
Therefore, the optimal scanning time was determined to
be between 40 to 60 min, as the standard error of the
values obtained during this time interval was the lowest.Table 1 Ratio of five ROIs over the cerebellum for 20 min-scans
Scanning time (min) Raphe nuclei Thalamus Basal
0 to 20 1,51 ± 0,07 1,64 ± 0,06 1,32
10 to 30 1,93 ± 0,06 2,02 ± 0,06 1,63
20 to 40 2,37 ± 0,05 2,40 ± 0,04 1,95
30 to 50 2,73 ± 0,04 2,69 ± 0,04 2,19
40 to 60 3,00 ± 0,04 2,89 ± 0,03 2,36
50 to 70 3,19 ± 0,04 2,99 ± 0,04 2,45
60 to 80 3,32 ± 0,05 3,10 ± 0,04 2,55
70 to 90 3,20 ± 0,07 3,03 ± 0,05 2,49
The values of the five ROIs correspond to the mean values of the five experiments ±
values of the right and left sides were taken for the four other regions
The standard error (SE) was the lowest for the values between 40 and 60 min of scQuantification of [11C]DASB regional activity
The BPND values were derived from the reference tissue
model MRTM2 using the cerebellum as a reference re-
gion (Table 2). These values were obtained for 18 ROIs
(raphe nuclei, hypothalamus, left and right thalamus, left
and right hippocampus, left and right frontal cortex, left
and right parietal cortex, left and right temporal cortex,
left and right occipital cortex, left and right basal gan-
glia, anterior cingulate gyrus, posterior cingulate gyrus),ganglia Frontal cortex Occipital cortex Mean SE
± 0,05 1,15 ± 0,03 1,09 ± 0,005 0.045
± 0,05 1,31 ± 0,02 1,07 ± 0,003 0.042
± 0,04 1,45 ± 0,02 1,05 ± 0,01 0.031
± 0,03 1,53 ± 0,01 1,03 ± 0,01 0.026
± 0,03 1,57 ± 0,01 1,01 ± 0,01 0.025
± 0,03 1,57 ± 0,02 1,00 ± 0,01 0.029
± 0,04 1,59 ± 0,02 1,00 ± 0,01 0.034
± 0,06 1,58 ± 0,03 1,02 ± 0,02 0.046
standard error. Except for the raphe nuclei (in the sagittal plane), the mean
anning, which was therefore determined as the optimal time interval
Table 2 BPND values obtained from MRTM2
MRTM2
Region BPND
Raphe nuclei 1,80 ± 0,37
Hypothalamus 1,75 ± 0,34
Hippocampus L 0,93 ± 0,43
Hippocampus R 0,85 ± 0,18
Thalamus L 1,75 ± 0,60
Thalamus R 1,70 ± 0,40
Frontal cortex R 0,50 ± 0,17
Frontal cortex L 0,50 ± 0,23
Basal ganglia R 1,15 ± 0,49
Basal ganglia L 1,27 ± 0,77
ACG 0,39 ± 0,26
PCG 0,25 ± 0,17
Temporal cortex R 0,26 ± 0,11
Temporal cortex L 0,28 ± 0,19
Occipital cortex R 0,05 ± 0,11
Occipital cortex L 0,05 ± 0,10
Parietal cortex R 0,17 ± 0,17
Parietal cortex L 0,20 ± 0,18
The BPND values for the MRTM2 method were automatically calculated using
PMOD software and correspond to the mean ± standard deviation of the five
experiments for 18 ROIs (raphe nuclei, hypothalamus, left and right thalamus,
left and right hippocampus, left and right frontal cortex, left and right parietal
cortex, left and right temporal cortex, left and right occipital cortex, left and
right basal ganglia, anterior cingulate gyrus, posterior cingulate gyrus). The
ROIs over the left and right cerebellum were used as the reference region
BP binding potential of the nondisplaceable compartment, L left, R right
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ing used as the reference region.
For the MRTM2, the k’2 value was calculated using
the Multilinear Reference Tissue Model (MRTM) as the
mean k2 (clearance rate constant from a region of inter-
est to plasma) value of five high-SERT binding regions:
raphe nuclei, right and left thalamus, right and left basal
ganglia. The mean value of the k’2 parameter for the five
experiments was 0.096 ± 0.013.Table 3 Semi-quantitative ratio analysis
Region Ratio Region
Raphe nuclei 3,03 ± 0,51 Frontal cortex R
Hypothalamus 2,85 ± 0,55 Frontal cortex L
Hippocampus L 2,07 ± 0,44 Basal ganglia R
Hippocampus R 2,05 ± 0,30 Basal ganglia L
Thalamus L 2,91 ± 0,75 ACG
Thalamus R 2,91 ± 0,54 PCG
Semi-quantitative values were obtained using the ratio analysis method: ratio of th
over the concentration of radioactivity within the cerebellum, using the data from 4
The values correspond to the mean ± standard deviation of the five experiments
Ratio ROI/cerebellum, L left; R rightGiven the results of the aforementioned scanning time
interval analysis, the semi-quantitative analysis was per-
formed using the data between 40 to 60 min. The ratios
of the concentration of radioactivity within the same 18
ROIs over the cerebellum are presented in Table 3.
Statistical analysis: comparison of methods
The correlation (R2) between the values obtained from
the reference tissue model MRTM2 and the semi-
quantitative ratio analysis using the data between 40 and
60 min was 99.3 % (two-tailed p-value < 0.01), and there-
fore statistically significant (Fig. 4).
Discussion
The primary objective of this study was to evaluate
the SERT density in the normal canine brain from
analysis of [11C]DASB regional distribution using PET
imaging. The highest radioactivity levels were ob-
served in the hypothalamus, raphe nuclei and thal-
amus, intermediate levels were observed in the basal
ganglia, hippocampus and frontal cortex, modest
levels in the anterior and posterior cingulate gyri and
temporal cortex, and low levels in the parietal cortex,
occipital cortex and cerebellum. These results are
consistent with the previous human [17–21, 39] and
animal [12, 14] studies.
As previously mentioned, the two parameters VT
and BP used to evaluate the [11C]DASB regional dis-
tribution can be estimated using invasive and time-
consuming kinetic methods such as 1TC, 2TC and
Logan graphical models which require the placement
of an arterial catheter. BP values can also be esti-
mated by reference tissue methods that represent a
noninvasive alternative method to evaluate the SERT
density of the canine brain, withdrawing the need of
arterial samples. A previous study compared the BPND
values obtained via a 2TC model with those calcu-
lated using several reference tissue models, the sim-
plified reference tissue model 2, the MRTM2 and the
Logan noninvasive model. The MRTM2 modelRatio Region Ratio
1,59 ± 0,25 Temporal cortex R 1,25 ± 0,20
1,57 ± 0,29 Temporal cortex L 1,27 ± 0,31
2,13 ± 0,74 Occipital cortex R 1,32 ± 0,52
2,22 ± 0,94 Occipital cortex L 1,29 ± 0,45
1,41 ± 0,38 Parietal cortex R 1,17 ± 0,21
1,22 ± 0,24 Parietal cortex L 1,21 ± 0,23
e concentration of radioactivity within the same 18 ROIs as for MRTM2 (Table 2)
0 to 60 min
Fig. 4 Correlation between the semi-quantitative ratio analysis and the reference tissue model MRTM2. The coefficient of determination (R2)
between the BPND values obtained from the MRTM2 and the values obtained from the semi-quantitative analysis was determined. The values
correspond to the five experiments for five ROIs over representative regions of high (raphe nuclei and thalamus), intermediate (basal ganglia and
frontal cortex) and low (occipital cortex) radioactivity concentration. Except for the raphe nuclei (in the sagittal plane), the mean values of the
right and left sides were taken for the four other regions. BPND = binding potential of the nondisplaceable compartment
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the 2TC, and was therefore chosen as reference tissue
method of choice in our study [40].
To perform the reference tissue methods, the cerebel-
lar cortex is selected as reference region. The properties
required for an ideal reference region are similar free
and nonspecific tracer binding properties as compared
to regions with specific binding, and negligible specific
binding of the radiotracer. Previously, the white matter
and occipital cortex were also tested as reference re-
gions. Although having very low levels of SERT, the pos-
sible difference of pharmacokinetics in free and
nonspecific compartments between white matter and
gray matter, caused the cerebellar cortex to become the
more commonly used reference region, even though it is
not completely devoid of SERT binding sites [41].
The second objective was to investigate the possibility
of replacing the dynamic scan by a static acquisition.
The influence of the scanning time was evaluated in
order to assess whether it would be possible to perform
a shorter (20 min) static acquisition instead of the
90 min dynamic acquisition for SERT binding estima-
tions in patients. Our results demonstrated that the
values show least variability between 40 and 60 min. In
human studies, ratios of radioactivity within the ROIs to
that in the cerebellum were calculated using data from
55 to 90 min after injection of the radiotracer [17, 18].
In our study, the ratio values were the most variable in
the late acquisition, from 70 to 90 min (SE = 4.6 %) des-
pite relative higher injected activity compared tohumans. The explanation could be the increase in noise
towards the end of the scan because of the physical
decay of the radionuclide (T1/2 of
11C = 20 min) [38].
For these reasons, it has been previously established in
human studies that there is no need to scan longer than
approximately 90 min [18, 20, 38].
Finally, a semi-quantitative analysis was performed by
measuring the ratio of the radioactivity within several
ROIs to the radioactivity within the cerebellum, using
the data from 40 to 60 min. This method correlated sig-
nificantly to the MRTM2 (R2 = 0.993). Therefore, a
20 min static acquisition performed 40 min after intra-
venous injection of [11C]DASB represents another more
convenient and faster alternative method to evaluate the
SERT of the canine brain in clinical surroundings.
The presence of [11C]DASB radiometabolites in the
brain and their potential interference with the measure-
ments cannot be excluded. Nevertheless, [11C]DASB is a
highly selective radiotracer with a high affinity for the
SERT [16]. Its radiometabolites are mainly polar and
therefore unlikely to cross the blood–brain barrier and
interfere with the measurements [17, 42].
Conclusions
Evaluation of the SERT in the canine brain can be per-
formed after administration of [11C]DASB using PET
imaging. Given the similarities between canine behav-
ioral disorders and human neuropsychiatric disorders,
the dog could represent a valuable model for research
about the involvement of the SERT in neuropsychiatry.
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the semi-quantitative ratio method based on a static
scan provide less invasive and more convenient alterna-
tives to the arterial sampling based kinetic analysis.
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